Brief: Kymera Therapeutics Announces Positive First-In-Human Results From Phase 1 Healthy Volunteer Clinical Trial Of KT-621
02/06/2025 13:31
June 2 (Reuters) - Kymera Therapeutics Inc KYMR.O: KYMERA THERAPEUTICS ANNOUNCES POSITIVE FIRST-IN-HUMAN RESULTS FROM PHASE 1 HEALTHY VOLUNTEER CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER KYMERA THERAPEUTICS INC - KT-621 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS KYMERA THERAPEUTICS INC - KT-621 PHASE 1B TRIAL DATA EXPECTED 4Q25 KYMERA THERAPEUTICS INC - PHASE 2B TRIALS IN AD AND ASTHMA TO START 4Q25 AND 1Q26 Source text: ID:nGNX7dPzLF Further company coverage: KYMR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kymera Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer